CLCA1 is Poorly Expressed in Stomach Adenocarcinoma and Correlates with Immune Infiltration

SUMMARY: Calcium-activated chloride channel regulator 1 (CLCA1) is associated with cancer progression. The expression and immunologic function of CLCA1 in stomach adenocarcinoma (STAD) remain unclear. In this investigation, the expression of CLCA1 in STAD tissues and its involvement in the progression and immune response of STAD were examined using databases such as cBioPortal, TISIDB, and UALCAN. In order to validate the expression level of CLCA1 protein in gastric adenocarcinoma, thirty clinical tissue specimens were gathered for immunohistochemical staining. The findings indicated a downregulation of CLCA1 in STAD patients, which was correlated with race, age, cancer grade, Helicobacter pylori infection, and molecular subtype. Through the examination of survival analysis, it was identified that diminished levels of CLCA1 within gastric cancer cases were linked to decreased periods of post-progression survival (PPS), overall survival (OS), and first progression (FP) (P<0.05). The CLCA1 mutation rate was lower in STAD, but the survival rate was higher in the variant group. The correlation between the expression level of CLCA1 and the levels of immune infiltrating cells in STAD, as well as the immune activating molecules, immunosuppressive molecules, MHC molecules, chemokines, and their receptor molecules, was observed. Gene enrichment analysis revealed that CLCA1 may be involved in STAD progression through systemic lupus erythematosus (SLE), proteasome, cell cycle, pancreatic secretion, and PPAR signaling pathways. In summary, CLCA1 is anticipated to function as a prognostic marker for patients with STAD and is linked to the immunization of STAD.

Saved in:
Bibliographic Details
Main Authors: Zhao,Xueying, Chen,Yunfan, Lu,Xinghao, Cheng,ZeNong, Lu,Jin
Format: Digital revista
Language:English
Published: Sociedad Chilena de Anatomía 2024
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022024000100173
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0717-95022024000100173
record_format ojs
spelling oai:scielo:S0717-950220240001001732024-01-25CLCA1 is Poorly Expressed in Stomach Adenocarcinoma and Correlates with Immune InfiltrationZhao,XueyingChen,YunfanLu,XinghaoCheng,ZeNongLu,Jin Stomach adenocarcinoma Clinical stages Immunohistochemistry Bioinformatics Prognostic factor SUMMARY: Calcium-activated chloride channel regulator 1 (CLCA1) is associated with cancer progression. The expression and immunologic function of CLCA1 in stomach adenocarcinoma (STAD) remain unclear. In this investigation, the expression of CLCA1 in STAD tissues and its involvement in the progression and immune response of STAD were examined using databases such as cBioPortal, TISIDB, and UALCAN. In order to validate the expression level of CLCA1 protein in gastric adenocarcinoma, thirty clinical tissue specimens were gathered for immunohistochemical staining. The findings indicated a downregulation of CLCA1 in STAD patients, which was correlated with race, age, cancer grade, Helicobacter pylori infection, and molecular subtype. Through the examination of survival analysis, it was identified that diminished levels of CLCA1 within gastric cancer cases were linked to decreased periods of post-progression survival (PPS), overall survival (OS), and first progression (FP) (P<0.05). The CLCA1 mutation rate was lower in STAD, but the survival rate was higher in the variant group. The correlation between the expression level of CLCA1 and the levels of immune infiltrating cells in STAD, as well as the immune activating molecules, immunosuppressive molecules, MHC molecules, chemokines, and their receptor molecules, was observed. Gene enrichment analysis revealed that CLCA1 may be involved in STAD progression through systemic lupus erythematosus (SLE), proteasome, cell cycle, pancreatic secretion, and PPAR signaling pathways. In summary, CLCA1 is anticipated to function as a prognostic marker for patients with STAD and is linked to the immunization of STAD.info:eu-repo/semantics/openAccessSociedad Chilena de AnatomíaInternational Journal of Morphology v.42 n.1 20242024-02-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022024000100173en10.4067/S0717-95022024000100173
institution SCIELO
collection OJS
country Chile
countrycode CL
component Revista
access En linea
databasecode rev-scielo-cl
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Zhao,Xueying
Chen,Yunfan
Lu,Xinghao
Cheng,ZeNong
Lu,Jin
spellingShingle Zhao,Xueying
Chen,Yunfan
Lu,Xinghao
Cheng,ZeNong
Lu,Jin
CLCA1 is Poorly Expressed in Stomach Adenocarcinoma and Correlates with Immune Infiltration
author_facet Zhao,Xueying
Chen,Yunfan
Lu,Xinghao
Cheng,ZeNong
Lu,Jin
author_sort Zhao,Xueying
title CLCA1 is Poorly Expressed in Stomach Adenocarcinoma and Correlates with Immune Infiltration
title_short CLCA1 is Poorly Expressed in Stomach Adenocarcinoma and Correlates with Immune Infiltration
title_full CLCA1 is Poorly Expressed in Stomach Adenocarcinoma and Correlates with Immune Infiltration
title_fullStr CLCA1 is Poorly Expressed in Stomach Adenocarcinoma and Correlates with Immune Infiltration
title_full_unstemmed CLCA1 is Poorly Expressed in Stomach Adenocarcinoma and Correlates with Immune Infiltration
title_sort clca1 is poorly expressed in stomach adenocarcinoma and correlates with immune infiltration
description SUMMARY: Calcium-activated chloride channel regulator 1 (CLCA1) is associated with cancer progression. The expression and immunologic function of CLCA1 in stomach adenocarcinoma (STAD) remain unclear. In this investigation, the expression of CLCA1 in STAD tissues and its involvement in the progression and immune response of STAD were examined using databases such as cBioPortal, TISIDB, and UALCAN. In order to validate the expression level of CLCA1 protein in gastric adenocarcinoma, thirty clinical tissue specimens were gathered for immunohistochemical staining. The findings indicated a downregulation of CLCA1 in STAD patients, which was correlated with race, age, cancer grade, Helicobacter pylori infection, and molecular subtype. Through the examination of survival analysis, it was identified that diminished levels of CLCA1 within gastric cancer cases were linked to decreased periods of post-progression survival (PPS), overall survival (OS), and first progression (FP) (P<0.05). The CLCA1 mutation rate was lower in STAD, but the survival rate was higher in the variant group. The correlation between the expression level of CLCA1 and the levels of immune infiltrating cells in STAD, as well as the immune activating molecules, immunosuppressive molecules, MHC molecules, chemokines, and their receptor molecules, was observed. Gene enrichment analysis revealed that CLCA1 may be involved in STAD progression through systemic lupus erythematosus (SLE), proteasome, cell cycle, pancreatic secretion, and PPAR signaling pathways. In summary, CLCA1 is anticipated to function as a prognostic marker for patients with STAD and is linked to the immunization of STAD.
publisher Sociedad Chilena de Anatomía
publishDate 2024
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022024000100173
work_keys_str_mv AT zhaoxueying clca1ispoorlyexpressedinstomachadenocarcinomaandcorrelateswithimmuneinfiltration
AT chenyunfan clca1ispoorlyexpressedinstomachadenocarcinomaandcorrelateswithimmuneinfiltration
AT luxinghao clca1ispoorlyexpressedinstomachadenocarcinomaandcorrelateswithimmuneinfiltration
AT chengzenong clca1ispoorlyexpressedinstomachadenocarcinomaandcorrelateswithimmuneinfiltration
AT lujin clca1ispoorlyexpressedinstomachadenocarcinomaandcorrelateswithimmuneinfiltration
_version_ 1792504459813715968